How Price Transparency Could Fix the Abandoned Rx Issue: Laura Jensen

Why It Matters

Prescription abandonment drives higher health‑care costs and poorer outcomes; transparent pricing offers a scalable solution that benefits patients, payers, and pharma manufacturers.

Key Takeaways

• ~1 billion U.S. prescriptions go unfilled each year due to cost
• Transparency reduces navigation complexity for chronic‑disease patients
• MFN and IRA policies could shrink traditional copay‑assistance
• GoodRx pushes manufacturers toward consumer‑centric discount models
• TrumpRx offers cash‑pay discounts, but early performance is uncertain

Pulse Analysis

Price transparency is emerging as a strategic lever for the pharmaceutical industry, especially as policymakers tighten the rules around drug pricing. The Inflation Reduction Act’s pricing negotiations and the looming Most‑Favored‑Nation (MFN) mandates threaten to curtail manufacturer‑sponsored copay assistance, a long‑standing tool for keeping patients on therapy. In this shifting landscape, platforms like GoodRx are redefining value creation by surfacing real‑time out‑of‑pocket costs and facilitating instant discounts, thereby turning transparency into a competitive differentiator rather than a compliance burden.

For patients with chronic conditions, the cost barrier translates directly into prescription abandonment—a phenomenon that costs the health‑care system billions in avoidable complications. Jensen’s remarks at Asembia’s AXS26 conference underscored that simplifying discount access—without requiring a deep understanding of insurance formularies—can dramatically improve adherence. By leveraging consumer‑facing tools that present clear price comparisons, pharma companies can maintain market share while meeting regulatory expectations, turning a potential threat into a growth opportunity.

The launch of TrumpRx illustrates how cash‑pay discount models are testing the market’s appetite for transparent pricing. Though its early performance data are mixed, the platform’s approach—offering lower out‑of‑pocket prices when patients forgo insurance—highlights a broader industry trend toward price‑visible, patient‑centric solutions. As MFN pricing frameworks mature, manufacturers that integrate transparent discount channels are likely to preserve patient loyalty and mitigate the financial impact of abandoned prescriptions, positioning themselves as leaders in a more open pharmaceutical ecosystem.